Morgan Stanley Bullish on Johnson & Johnson's Future Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Johnson & Johnson Upgrade: Morgan Stanley upgraded Johnson & Johnson (JNJ) from Equal-Weight to Overweight, projecting a revenue and earnings per share CAGR of approximately 5.5% and 12% from 2026 to 2030, indicating a favorable growth outlook compared to its biopharma peers.
- Price Target Increase: Analyst Terence Flynn raised the price target for JNJ from $200 to $262 per share, noting that the stock is trading at about a 3x discount to the S&P 500, suggesting significant upside potential.
- Applied Materials Upgrade: Mizuho Securities upgraded Applied Materials (AMAT) from Neutral to Outperform, anticipating benefits from rising capital expenditures in the U.S., Taiwan, and Japan, with a price target increase from $275 to $370, reflecting optimism about future market demand.
- Pinterest Downgrade: HSBC Global Investment Research downgraded Pinterest (PINS) from Buy to Hold, citing a softer near-term outlook after the company cut 15% of its workforce to reallocate resources to AI roles, with North America's ARPU growth lagging at only 6%, indicating pressure on short-term profitability.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 227.290
Low
190.00
Averages
218.50
High
240.00
Current: 227.290
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Aims for Historic $100 Billion Sales Milestone
- Strong Sales Growth: Johnson & Johnson reported a 9.1% year-over-year increase in Q4 2025 sales to $24.6 billion, with adjusted earnings per share rising 20.6% to $2.46, demonstrating robust profitability in a competitive market.
- Historic Sales Target: The company projects 2026 sales between $100 billion and $101 billion, marking its first-ever annual sales exceeding $100 billion, which underscores its leadership in the biopharma sector.
- Navigating Patent Expiry Challenges: Despite losing patent exclusivity for the immunology drug Stelara in Europe and the U.S., Johnson & Johnson maintained stable performance through a diversified product lineup and medtech division, with Xarelto's sales increasing 11% year-over-year to $2.6 billion, showcasing the resilience of its product portfolio.
- Consistent Dividend Growth: As a
Continue Reading
Johnson & Johnson's Akeega Receives New EU Indication Approval
- New Indication Approval: Johnson & Johnson's prostate cancer therapy Akeega has received support from the EMA expert panel, recommending its use as a combination therapy for metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations, marking a significant expansion in the company's oncology portfolio.
- Clinical Data Support: This decision is backed by data from J&J's Phase 3 AMPLITUDE study, which successfully met the primary endpoint of radiographic progression-free survival, demonstrating Akeega's efficacy in the new indication and providing patients with an additional treatment option.
- Market Potential: Akeega is already available in the EU for patients with BRCA-mutated metastatic castration-resistant prostate cancer, and the new indication is expected to broaden its market reach, potentially driving revenue growth for Johnson & Johnson in the oncology sector.
- Subsequent Approval Process: The positive opinion will be reviewed by the European Commission for final approval, and if granted, it will further strengthen Johnson & Johnson's market position in prostate cancer treatment, solidifying its leadership in the pharmaceutical industry.
Continue Reading